

REGD. OFFICE: "11/12 UDYOG NAGAR, S.V. ROAD, GOREGAON (WEST), MUMBAI-400 104."  
TEL: 91-22 6760 7080; FAX: 91-22 6760 7070, EMAIL: raveendran@themismedicare.com

**CIN:U24239MH1991IPLC059995**

Date: 24<sup>th</sup> July, 2021

**BSE Limited**  
**Phiroze Jeejeebhoy Towers,**  
**Dalal Street, Mumbai 400 001**  
Email: [corp.relations@bseindia.com](mailto:corp.relations@bseindia.com)

Dear Sirs

**CORRIGENDUM**

**Sub: Prior Intimation under regulation 10(5) of Securities and Exchange Board of India {Substantial Acquisition of Shares and Takeovers} Regulations, 2011 for proposed acquisition of shares.**

We write this in continuation to our letter dated 24<sup>th</sup> July 2021, enclosing therewith intimation/disclosure under regulation 10(5) of Securities and Exchange Board of India {Substantial Acquisition of Shares and Takeovers} Regulations, 2011.

In this connection, we have to state that, there was an inadvertent error in point no. 11 of the intimation/disclosure under Regulation 10(5) of Securities and Exchange Board of India {Substantial Acquisition of Shares and Takeovers} Regulations, 2011.

Point no. 11 should be read as mentioned below:

| 11 | Shareholding Details                                                                                       | Before the proposed Transaction |                                               | After the proposed transaction   |                                         |
|----|------------------------------------------------------------------------------------------------------------|---------------------------------|-----------------------------------------------|----------------------------------|-----------------------------------------|
|    | a. Acquirer(s)<br>Pharmaceutical<br>Business Group(India)<br>Limited<br>and PACs (other than<br>sellers) - | No of Shares/voting<br>rights   | % w.r.t<br>total<br>share<br>capital of<br>TC | No of<br>Shares/voting<br>rights | % w.r.t total<br>share capital<br>of TC |
| 1. | Pharmaceutical Business<br>Group [India] Ltd                                                               | 35,82,000                       | 24.65                                         | 74,32,000                        | 51.15                                   |
| 2. | Themis Medicare Limited                                                                                    | 33,69,605                       | 23.19                                         | 33,69,605                        | 23.19                                   |
| 3. | Jayshree D Patel                                                                                           | 70,645                          | 0.49                                          | 70,645                           | 0.49                                    |
| 4. | Sachin Dinesh Patel                                                                                        | 7,100                           | 0.05                                          | 7,100                            | 0.05                                    |
| 5. | Reena S Patel                                                                                              | 5,600                           | 0.04                                          | 5,600                            | 0.04                                    |
| 6. | Dinesh Shantilal Patel                                                                                     | 4,701                           | 0.03                                          | 4,701                            | 0.03                                    |
| 7. | Anay Rupen Choksi                                                                                          | 3,047                           | 0.02                                          | 3,047                            | 0.02                                    |
| 8. | Nysha Rupen Choksi                                                                                         | 3,047                           | 0.02                                          | 3,047                            | 0.02                                    |
|    | <b>Total</b>                                                                                               | <b>70,45,745</b>                | <b>48.49%</b>                                 | <b>1,08,95,745</b>               | <b>74.99%</b>                           |
|    | b. Seller (s) Yuhan<br>Corporation                                                                         | 38,50,000                       | 26.50%                                        | NIL                              | NIL                                     |

**Pharmaceutical  
Business Group  
(India) Limited**

---

REGD. OFFICE: "11/12 UDYOG NAGAR, S.V. ROAD, GOREGAON (WEST), MUMBAI-400 104."  
TEL: 91-22 6760 7080; FAX: 91-22 6760 7070, EMAIL: raveendran@themismedicare.com

---

**CIN:U24239MH1991IPLC059995**

Please take the same on your record.

Thanking you,

Yours faithfully,

**For Pharmaceutical Business Group (India) Limited**

**Jayshree D. Patel**  
**Director**

---

REGD. OFFICE: "11/12 UDYOG NAGAR, S.V. ROAD, GOREGAON (WEST), MUMBAI-400 104."  
TEL: 91-22 6760 7080; FAX: 91-22 6760 7070, EMAIL: [raveendran@themismedicare.com](mailto:raveendran@themismedicare.com)

---

CIN:U24239MH1991IPLC059995

To,  
Rakesh Parekh  
Special Assistant  
Listing Compliance  
BSE Ltd.  
P J Towers, Dalal Street,  
Mumbai - 400001, India.  
Email: [corp.relations@bseindia.com](mailto:corp.relations@bseindia.com)

Dear Sirs,

**Sub: Revised Disclosure of Inter-se Transfer of Shares between the Promoters/ Promoters Group in accordance with Regulation 10(5) of SEBI (SAST) Regulations, 2011.**


With reference to your email dated 26<sup>th</sup> July, 2021 asking for the revised rectify disclosure under regulation 10(5) of Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Please take the same on record the revised rectified disclosure under regulation 10(5) of Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

CC to;  
Company: [secretary@gtbl.in.net](mailto:secretary@gtbl.in.net)

Thanking you,

Yours faithfully,  
**For Pharmaceutical Business Group (India) Limited**



**Kersasp Kalianwala**  
Director



Revised Disclosure under regulation 10 (5)

|   |                                                                                                                                                                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                         |
|---|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1 | Name of the Target Company                                                                                                                                                                                                                                                                                                                                                                                          | Gujarat Themis Biosyn Limited                                                                                                                                                                                                           |
| 2 | Name of the Acquirer                                                                                                                                                                                                                                                                                                                                                                                                | Pharmaceutical Business Group (India) Limited                                                                                                                                                                                           |
| 3 | Whether the acquirer(s) is/ are promoters of the TC prior to the transaction.<br><br>If not, nature of relationship or association with the TC or its promoters                                                                                                                                                                                                                                                     | Yes.<br>Pharmaceutical Business Group (India) Limited is one of the promoters of the Target Company.<br><br>Not applicable                                                                                                              |
| 4 | Details of the proposed acquisition<br><br>a. Name of the person(s) from whom shares are acquired<br><br>b. Proposed date of Acquisition<br><br>c. Number of shares to be acquired from each person mentioned in 4 (a) above<br><br>d. Total shares to be acquired as % of share capital of TC .<br><br>e. Price at which shares are proposed to be acquired<br><br>f. Rationale, if any, for the proposed transfer | Yuhan Corporation<br><br>On or after July 30, 2021<br><br>38,50,000<br><br>(26.50 %)<br><br>Rs. 150/- per share<br><br>Inter-se transfer of shares amongst promoters of the Company, as per the mutual agreement between the promoters. |



Revised Disclosure under regulation 10 (5)

|    |                                                                                                                                                                                                                                                                                 |                                                                                                                                                                         |
|----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 5  | Relevant sub-clause of regulation 10(1)(a) under which the acquirer is exempted from making open offer                                                                                                                                                                          | Regulation 10(1)(a)(ii) of SEBI (SAST) Regulation, 2011                                                                                                                 |
| 6  | If, frequently traded, volume weighted average market price for a period of 60 trading days preceding the date of issuance of this notice as traded on BSE Ltd, the stock exchange where the maximum volume of trading in the shares of the TC are recorded during such period. | Rs. 310.64 Per share                                                                                                                                                    |
| 7  | If in-frequently traded, the price as determined in terms of clause (e) of sub-regulation (2) of regulation 8.                                                                                                                                                                  | Not applicable                                                                                                                                                          |
| 8  | Declaration by the acquirer, that the acquisition price would not be higher by more than 25% of the price computed in point 6 or point 7 as applicable.                                                                                                                         | The Acquirer hereby declares that the acquisition price shall not be higher than 25% of the price mentioned in (6) above.<br>-                                          |
| 9  | Declaration by the acquirer, that the transferor and transferee have complied / will comply with applicable disclosure requirements in Chapter V of the Takeover Regulations, 2011 (corresponding provisions of the repealed Takeover Regulations 1997)                         | Yes, the Acquirer hereby declares that the transferor and transferee have complied with applicable disclosure requirement in Chapter V of the Takeover Regulation, 2011 |
| 10 | Declaration by the acquirer that all the conditions specified under regulation 10(1)(a) with respect to exemptions has been duly complied with                                                                                                                                  | The Acquirer hereby declares that all the conditions specified under regulation 10 (1) (a) with respect to exemption has been complied with.                            |



Revised Disclosure under regulation 10 (5)

| 11 | Shareholding Details                                                                        | Before the proposed Transaction |                                   | After the proposed transaction |                                   |
|----|---------------------------------------------------------------------------------------------|---------------------------------|-----------------------------------|--------------------------------|-----------------------------------|
|    | a. Acquirer(s) and PACs (other than sellers) - Pharmaceutical Business Group(India) Limited | No of Shares/voting rights      | % w.r.t total share capital of TC | No of Shares/voting rights     | % w.r.t total share capital of TC |
| 1. | Pharmaceutical Business Group [India] Ltd                                                   | 35,82,000                       | 24.65                             | 74,32,000                      | 51.15                             |
| 2. | Themis Medicare Limited                                                                     | 33,69,605                       | 23.19                             | 33,69,605                      | 23.19                             |
| 3. | Jayshree D Patel                                                                            | 70,645                          | 0.49                              | 70,645                         | 0.49                              |
| 4. | Sachin Dinesh Patel                                                                         | 7,100                           | 0.05                              | 7,100                          | 0.05                              |
| 5. | Reena S Patel                                                                               | 5,600                           | 0.04                              | 5,600                          | 0.04                              |
| 6. | Dinesh Shantilal Patel                                                                      | 4,701                           | 0.03                              | 4,701                          | 0.03                              |
| 7. | Anay Rupen Choksi                                                                           | 3,047                           | 0.02                              | 3,047                          | 0.02                              |
| 8. | Nysha Rupen Choksi                                                                          | 3,047                           | 0.02                              | 3,047                          | 0.02                              |
|    | <b>Total</b>                                                                                | <b>70,45,745</b>                | <b>48.49%</b>                     | <b>1,08,95,745</b>             | <b>74.99%</b>                     |
|    | b. Seller (s) Yuhan Corporation                                                             | 38,50,000                       | 26.50%                            | NIL                            | NIL                               |

For **Pharmaceutical Business Group (India) Limited**

*Kersasp Kalianwala*

**Kersasp Kalianwala**

**Director**

**Place: Mumbai**

**Date: July 26, 2021**



---

REGD. OFFICE: "11/12 UDYOG NAGAR, S.V. ROAD, GOREGAON (WEST), MUMBAI-400 104."  
TEL: 91-22 6760 7080; FAX: 91-22 6760 7070, EMAIL: raveendran@themismedicare.com

---

CIN:U24239MH1991IPLC059995

DECLARATION BY PHARMACEUTICAL BUSINESS GROUP (INDIA) LIMITED (THE ACQUIRER) Regulation  
10(5)

The Acquirer hereby declares that the acquisition price shall not be higher than 25% of the price mentioned in (6) above.

The Acquirer hereby declares that the transferor and transferee have complied with applicable disclosure requirement in Chapter V of the Takeover Regulations, 2011.

The Acquirer hereby declares that all the conditions specified under regulation 10 (1) (a) with respect to exemption has been complied with.

For PHARMACEUTICAL BUSINESS GROUP (INDIA) LIMITED



Kersasp Kalianwala  
Director

